先聲藥業(02096.HK):與安諦康就抗流感藥物ADC189訂立合作協議
格隆匯10月10日丨先聲藥業(02096.HK)宣佈,2023年10月10日,集團與嘉興安諦康生物科技有限公司("安諦康")就創新藥ADC189("該產品")訂立合作協議(。根據該協議,集團將獲得該產品在中國於流行性感冒("流感")適應症的獨家商業化權益。本次合作將進一步強化集團在抗感染領域的產品佈局。
公吿顯示,ADC189是一種抗流感的聚合酶酸性蛋白(PA)抑制劑,通過抑制流感病毒中的CAP帽狀—依賴型核酸內切酶(CEN),ADC189可直接抑制病毒的複製,對抗甲型流感和乙型流感。臨牀前研究顯示,ADC189具有無中樞神經系統副作用、口服吸收不受食物影響、更高安全劑量等優勢。對比奧司他韋需要連服5天,ADC189全程口服劑量僅為「一粒」,並可在24小時內阻斷流感病毒複製,未來有望為廣大患者(包括兒童患者)帶來極大便利。目前,ADC189治療流感III臨牀試驗正順利推進中。
據瞭解,安諦康是一家聚焦呼吸道抗感染新藥開發和產業化的生物醫藥高科技公司,團隊由多位國內頂尖科學家、院士領銜。依託其DMPK新藥發現的平台優勢,安諦康的創新產品管線在呼吸道抗感染領域和婦科領域均有佈局,包括流感、呼吸道合胞病毒、子宮內膜異位症口服藥和子宮肌瘤等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.